- Home
- DSGX vs PCVX Comparison
DSGX vs PCVX Comparison
Compare DSGX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | PCVX |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.0B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DSGX | PCVX |
|---|---|---|
| Price | $80.70 | $60.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $105.22 | $88.25 |
| AVG Volume (30 Days) | 477.7K | ★ 952.1K |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.56 | $30.81 |
| 52 Week High | $108.51 | $65.00 |
Technical Indicators
Market Signals| Indicator | DSGX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 55.31 |
| Support Level | $69.53 | $52.18 |
| Resistance Level | $90.02 | $63.52 |
| Average True Range (ATR) | 2.43 | 2.28 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 68.06 | 53.37 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.